Effect of one-year lumacaftor –ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients

Cystic-fibrosis-related diabetes (CFRD) represents one of the most frequent extra pulmonary complications of CF. It is associated with worse clinical outcomes and higher mortality rates [1,2].

Source: Journal of Cystic Fibrosis - March 18, 2020 Category: Respiratory Medicine Authors: Bastien Misgault, Eva Chatron, Quitterie Reynaud, Sandrine Touzet, Michel Abely, Laurent Melly, St éphane Dominique, Françoise Troussier, Olivia Ronsin-Pradel, Michèle Gerardin, Julie Mankikian, Laure Cosson, Raphael Chiron, Leila Bounyar, Michel Porzi Source Type: research